Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
This is due to epigenetic components: microRNA, histone and DNA methylation, gene mutations that alter the expression and production of the neurotrophic factor BDNF, which interacts with the receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback